预约演示
更新于：2025-08-16
Droperidol
氟哌利多
更新于：2025-08-16
概要
基本信息
药物类型 小分子化药 |
别名 1-(1-(3-(p-fluorobenzoyl)propyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone、1-(1-(4-(p-fluorophenyl)-4-oxobutyl)-1,2,3,6-tetrahydro-4-pyridyl)-2-benzimidazolinone、Droperidol (JP17/USP/INN) + [10] |
作用方式 拮抗剂 |
作用机制 D2 receptor拮抗剂(多巴胺D2受体拮抗剂) |
非在研适应症 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1970-06-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H22FN3O2 |
InChIKeyRMEDXOLNCUSCGS-UHFFFAOYSA-N |
CAS号548-73-2 |
关联
38
项与 氟哌利多 相关的临床试验NCT07015528
Assessment of Drug Liking In Peri-procedural Clinical Settings
ChiCTR2500097291
Effect of droperidol on postoperative nausea and vomiting in patients undergoing bariatric surgery: a single-center, prospective, randomized controlled study
NCT06726811
Low-Dose Droperidol and Its Association with QTc Interval Changes in Emergency Department Patients
100 项与 氟哌利多 相关的临床结果
登录后查看更多信息
100 项与 氟哌利多 相关的转化医学
登录后查看更多信息
100 项与 氟哌利多 相关的专利（医药）
登录后查看更多信息
2,808
项与 氟哌利多 相关的文献（医药）2025-11-01AMERICAN JOURNAL OF EMERGENCY MEDICINE
Droperidol vs. haloperidol for abdominal pain
Article
作者: Gilbert, Brian W ; Luyten, Dylan R ; Di Paola, Sean G ; Lentz, Aaron P ; Gilt, Sebastian ; Townsend, Brock R ; Nisly, Andrea E
INTRODUCTION:
Haloperidol and droperidol are antipsychotic medications with multimodal pharmacodynamic effects making them useful in the emergency department (ED). Data suggests that droperidol and haloperidol may reduce morphine milliequivalents (MME) administered when used for undifferentiated abdominal pain (UAP) in the ED. However, there is a paucity of data comparing the two agents in this cohort. The purpose of this study was to assess the efficacy of haloperidol versus droperidol in reducing MME requirements for UAP in the ED.
METHODS:
This retrospective, single-center study included patients ≥18 years old who presented to the ED for UAP. Patients were excluded if they required urgent surgery or received haloperidol or droperidol for agitation. The primary outcome was the difference in MME administered in the ED between patients who received haloperidol versus droperidol. Secondary outcomes included rates of rescue antiemetics, rescue analgesics, admission to the hospital, hospital length of stay, and adverse effects.
RESULTS:
A total of 100 patients were evaluated, with 50 patients receiving haloperidol and 50 patients receiving droperidol. Patients in the haloperidol group received a lower median MME compared to those in the droperidol group (0 MME [IQR 0-10] vs 10 MME [IQR 0-20], p-value 0.033). There was no statistical difference between secondary outcomes evaluated, including safety events.
CONCLUSION:
Haloperidol was associated with a significant reduction in MME administration compared to droperidol for UAP in the ED. Large high-quality data sets are needed to confirm haloperidol's role in multimodal pain management of UAP compared to droperidol.
2025-10-01TOXICOLOGY IN VITRO
CiPA-qualified human iPSC-derived cardiomyocytes: A new frontier in toxicity testing by evaluating drug-induced arrhythmias
Article
作者: Sarkar, Jaganmay ; Khanna, Amit ; Bhanushali, Paresh ; Lickiss, Bettina ; Linder, Peter ; More, Shruti ; Konala, Vijay Bhaskar Reddy ; Kuhikar, Rutuja ; Gossmann, Matthias
Drug-induced arrhythmias remain a significant challenge in drug development, often leading to serious cardiovascular complications and the withdrawal of approved drugs from the market. The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative aims to enhance cardiac safety assessment by leveraging human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). In this study, we evaluated the effects of 28 drugs on a well-characterized hiPSC-CMs (YBLiCardio, Yashraj Biotechnology Ltd., Mumbai, India) using Electric Field Potential (EFP) measurements. The CardioExcyte 96 system recorded extracellular signals from 96 wells, functioning similarly to microelectrode arrays. Each drug was tested at four concentrations, and the effects were analyzed based on dynamic changes in beat patterns, with QT prolongation assessed by measuring the interval between the sodium spike and T-wave. Our results demonstrated that YBLiCardio cells responded to all drugs in line with the findings from the HESI CiPA study. Notably, droperidol (173 %) and domperidone (182 %), originally classified as intermediate-risk compounds, were identified as high-risk in our model, consistent with previous findings by Nguyen et al. (2017). Additionally, YBLiCardio showed enhanced predictive accuracy for chlorpromazine. These findings highlight the potential of hiPSC-CMs for proarrhythmia risk assessment within the CiPA framework, complementing ion channel data and in silico modeling approaches. Overall, YBLiCardio provides a robust and physiologically relevant platform for predicting cardiotoxicity, supporting safer and more efficient pre-clinical drug discovery & development.
2025-08-01ANNALS OF EMERGENCY MEDICINE
Efficacy and Safety of Pharmacologic Therapies for Nausea and Emesis in the Emergency Department: A Systematic Review and Bayesian Network Meta-analysis
Article
作者: Thode, Henry ; Shrestha, Pragati ; Singer, Adam ; deSouza, Ian S ; Allen, Robert ; Koos, Jessica
OBJECTIVES:
We conducted a systematic review and Bayesian network meta-analysis to identify the most effective and safest therapies for nausea/emesis in adult patients presenting to the emergency department (ED).
METHODS:
We searched PubMed, Embase, Cumulated Index to Nursing and Allied Health Literature, and Web of Science from inception to November 22, 2023. Eligible studies were randomized controlled trials in adult participants presenting to ED with nausea or emesis and compared one pharmacologic therapy with another or placebo. Outcomes were as follows: (1) change in nausea intensity at 30 minutes, (2) need for rescue drug, and (3) significant adverse reaction. We extracted data according to Preferred Reporting Items for Systematic Reviews and Network Meta-Analysis and appraised studies using Cochrane RoB 2. We performed Bayesian network meta-analysis to calculate odds ratios with 95% credible intervals and frequentist network meta-analysis to calculate mean differences with 95% confidence intervals. We assessed confidence using Confidence in Network Meta-analysis. We ranked agents using surface under the cumulative ranking curve (SUCRA).
RESULTS:
Intravenous tropisetron (SUCRA=93.9%) is most likely superior for "need for rescue drug" (not needing rescue drug) (11 trials; n=1,465). Intravenous ondansetron (SUCRA=78.6%) is most likely superior for "significant adverse reaction" (not causing adverse reaction) (9 trials; n=1,267). The network for change in nausea intensity demonstrated statistically significant incoherence at the overall level.
CONCLUSION:
Within a minimally contextualized framework, as single agents, intravenous tropisetron and intravenous prochlorperazine are definitely among the most effective, intravenous metoclopramide and intravenous droperidol are possibly among the most effective, and oral ondansetron is definitely among the least effective; considering certain adverse reactions, intravenous metoclopramide, intravenous droperidol, and intravenous promethazine are definitely among the most harmful.
100 项与 氟哌利多 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 1989-01-01 | |
| 麻醉 | 日本 | 1971-05-10 | |
| 恶心和呕吐 | 美国 | 1970-06-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 32 | (Haloperidol) | 範選齋築夢繭壓壓築窪(蓋鹹窪簾繭蓋鑰選遞鬱) = 構鏇鏇鹹願膚鏇觸繭淵 蓋壓艱醖範蓋鑰製蓋鑰 (願壓醖鏇網願網襯鏇鹹, 3.30) 更多 | - | 2025-05-21 | ||
(Droperidol) | 範選齋築夢繭壓壓築窪(蓋鹹窪簾繭蓋鑰選遞鬱) = 鬱衊遞醖製廠築衊壓窪 蓋壓艱醖範蓋鑰製蓋鑰 (願壓醖鏇網願網襯鏇鹹, 3.04) 更多 | ||||||
N/A | 322 | DEX, OND, and placebo | 壓艱夢積築觸鑰壓襯窪(鹹餘齋壓簾窪窪範鹽窪) = 淵獵選願遞製衊鬱範製 網廠繭鑰鬱製網艱獵鑰 (糧壓鏇廠築鏇積衊齋網 ) | - | 2017-06-01 | ||
DEX, OND, and DRO | 壓艱夢積築觸鑰壓襯窪(鹹餘齋壓簾窪窪範鹽窪) = 夢構顧糧積齋網襯蓋製 網廠繭鑰鬱製網艱獵鑰 (糧壓鏇廠築鏇積衊齋網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用